New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
07:06 EDTBMY, AGENAgenus initiates Prophage Phase 2 trial
Agenus (AGEN) announced initiation of a randomized Phase 2 trial with Prophage for melanoma, and Bristol-Myers Squibb's (BMY) Yervoy for the treatment of Stage III and IV metastatic melanoma. The combination has the potential to trigger a more effective immune response against the tumor than Yervoy alone. The Phase 2, randomized, open label, single-center, investigator-sponsored trial is designed to evaluate the safety, feasibility and immunogenicity of the combination of Prophage vaccine and Yervoy with or without low dose cyclophosphamide in 25 patients with unresectable Stage III or IV metastatic melanoma. Jorge Quesada, principal investigator of the study said "The combination may improve the prospects for patients who do not respond to ipilimumab alone, which is approximately 70% of the metastatic melanoma patients."
News For AGEN;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
09:41 EDTBMYBristol-Myers up after Phase III Opdivo study met endpoint, trial stopped early
Subscribe for More Information
09:36 EDTBMYActive equity options trading on open
Subscribe for More Information
09:08 EDTBMYBristol-Myers data should be positive, says SunTrust
SunTrust expects the AACR data for Bristol-Myers' CheckMate-069 Opdivo + Yervoy combo, a treatment for melanoma, to show a positive overall response rate and progressive free survival that exceeds its prior -0004 results. The firm notes that the data is due to be presented on April 20. It raised its 2020 Opdivo revenue estimate to $7.1B versus the Street's $6.9B and raised its price target o n he stock to $74 from $70 while keeping a Buy rating on the shares.
08:58 EDTBMYBristol-Myers jumps 4% after Opdivo study stopped early after meeting endpoint
Subscribe for More Information
08:56 EDTBMYBristol-Myers says Phase III Opdivo study met endpoint, trial stopped early
Subscribe for More Information
April 16, 2015
12:16 EDTBMYEli Lilly and Bristol-Myers restructure Erbitux collaboration in N. America
Subscribe for More Information
08:59 EDTBMYGene therapy companies could benefit from increased attention, says Roth Capital
Subscribe for More Information
April 15, 2015
09:08 EDTBMYOn The Fly: Pre-market Movers
Subscribe for More Information
07:41 EDTAGEN, BMYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
07:03 EDTBMYLexicon and Bristol-Myers select development candidate for neuropathic pain
Subscribe for More Information
April 8, 2015
08:08 EDTBMYuniQure price target raised to $50 from $28 at Leerink
Subscribe for More Information
08:06 EDTBMYBristol-Myers completes acquisition of Flexus Biosciences
Bristol-Myers Squibb Company announced that it has completed the previously announced planned acquisition of Flexus Biosciences, Inc. The transaction includes full rights to F001287, Flexus’ lead preclinical, small-molecule IDO1-inhibitor targeted for IND filing in the second half of 2015 and an IDO/TDO discovery program that includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries. A newly formed entity established by the current shareholders of Flexus will retain, from and after the closing, all non-IDO/TDO assets of Flexus including those related to Flexus’ Phase 1 FLT3 and CDK4/6 inhibitor, its earlier stage small-molecule Treg cancer immunotherapy programs, and its current personnel and facilities.
07:06 EDTAGENAgenus acquires Celexion assets for $1M in cash, $3M in stock
Subscribe for More Information
April 7, 2015
07:14 EDTBMYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
April 6, 2015
16:17 EDTBMYOn The Fly: Closing Wrap
Subscribe for More Information
12:44 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
12:13 EDTBMYuniQure price target raised to $40 from $35 at Piper Jaffray
Subscribe for More Information
08:13 EDTBMYCelldex announces initiation of Phase 1/2 study of Varlilumab combination
Subscribe for More Information
07:33 EDTBMYBristol-Myers announces strategic collaboration with uniQure
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use